HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
Investing.com -- HSBC downgraded several major biotech names this week, citing macroeconomic sensitivities, tariff risks, and growing pressure from regulatory changes. Most notably, the bank downgraded Lilly to Reduce from Buy.